Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $304.95

Ascendis Pharma A/S (NASDAQ:ASND) has been given a consensus rating of “Buy” by the twenty brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $310.05.

A number of brokerages have recently issued reports on ASND. Barclays dropped their price objective on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $327.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st. UBS Group set a $345.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, August 31st. Evercore reiterated an “outperform” rating and issued a $329.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, Stifel Nicolaus lowered their price target on Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating on the stock in a research report on Monday, August 31st.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $270.56 on Tuesday. Ascendis Pharma A/S has a 12 month low of $186.05 and a 12 month high of $282.15. The company’s fifty day simple moving average is $257.84 and its 200-day simple moving average is $240.69. The firm has a market cap of $16.88 billion, a PE ratio of 20.99 and a beta of 0.35. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Equities research analysts expect that Ascendis Pharma A/S will post 5.15 EPS for the current fiscal year.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean-Jacques Bienaimé bought 2,000 shares of Ascendis Pharma A/S stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares in the company, valued at $714,357. The trade was a 222.22% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 40.00% of the company’s stock.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors have recently bought and sold shares of ASND. Cetera Investment Advisers acquired a new stake in Ascendis Pharma A/S during the second quarter worth approximately $552,000. Rhumbline Advisers lifted its position in Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 55 shares during the period. Daiwa Securities Group Inc. grew its stake in Ascendis Pharma A/S by 66.2% during the second quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company’s stock worth $645,000 after buying an additional 1,488 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in Ascendis Pharma A/S by 83.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock valued at $34,700,000 after buying an additional 91,412 shares during the period. Finally, Squarepoint Ops LLC bought a new position in Ascendis Pharma A/S in the 2nd quarter valued at about $897,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.